Theravet lists on Euronext Paris and Euronext Brussels

Back

Enrico Bastianelli, Chief Executive Officer of Theravet, opens the trading day in Paris

Theravet S.A. is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets.
At the end of 2020, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.